scholarly journals Target Therapy for Kidney Cancer

2020 ◽  
Author(s):  
Yang Wang ◽  
Lingxiang Liu
Keyword(s):  
Kidney Cancer ◽  
Target Therapy

Surgical benefits for patients with metastatic kidney cancer compared with target therapy and prognostic factors role to decide treatment tactic

2017 ◽  
Vol 16 (5) ◽  
pp. e2178-e2179
Author(s):  
A. Matulevičius ◽  
F. Jankevičius ◽  
A. Ulys ◽  
A. Patašius
Keyword(s):  
Prognostic Factors ◽  
Kidney Cancer ◽  
Target Therapy

scholarly journals Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database

2021 ◽  
Vol 8 ◽  
Author(s):  
Cheng Li ◽  
Ruiliang Wang ◽  
Wenchao Ma ◽  
Shenghua Liu ◽  
Xudong Yao
Keyword(s):  
Surgical Resection ◽  
Kidney Cancer ◽  
Real World ◽  
Primary Tumor ◽  
Target Therapy ◽  
Tumor Site ◽  
Seer Database ◽  
Cytoreductive Nephrectomy ◽  
Cancer Specific Survival ◽  
Primary Tumor Site

Introduction: The benefit of cytoreductive nephrectomy (CN) for metastatic kidney cancer has been challenged recently. The study aimed to evaluate the prognostic roles of surgical resection of primary tumor site for metastatic kidney cancer under a real-world setting.Methods: The Surveillance, Epidemiology, and End Results (SEER) database (2010–2015) and the overall survival (OS) and cancer-specific survival (CSS) were evaluated using the Cox proportional hazards regression model. One-to-one matching using the propensity score was used to estimate and compare the survival rates.Results: The SEER data contain records of 8,932 patients from 2010 to 2015. The data showed that 61.7% of the patients underwent CN while 38.2% did not receive any surgery. The median survival month for a patient without surgery was 4 months and for a patient with surgery was 19 months. The multivariate analysis showed that surgical resection of the primary tumor site was an independent favorable predictor for both OS and CSS (all p < 0.001) in the original and the matching cohort.Conclusions: In the era of target therapy, CN might still be a vital method to treat metastatic kidney cancer.

scholarly journals Personalized approach to the treatment of metastatic kidney cancer

2020 ◽  
pp. 63-67
Author(s):  
G. N. Alrkseeva ◽  
L. I. Gurina ◽  
L. F. Pisareva ◽  
M. V. Volkov ◽  
N. V. Cherdyntseva
Keyword(s):  
Kidney Cancer ◽  
Target Therapy ◽  
Sequential Therapy ◽  
Organizational Form ◽  
Target Line ◽  
Economic Effectiveness ◽  
Cancer Register ◽  
Line Therapy ◽  
Personalized Approach

Objective: Develop a new organizational form of a personalized approach to assign a target therapy to the patients with metastatic nephrocellular cancer concerning its clinical and economic effectiveness.Methods: The data by cancer register of the Primorsky region were used. 446 patients are included in the register, it allowed to estimate clinical-economic effectiveness of the target therapy by studying 88 cases.Results: 5 medicines were used: sunitrib, soraphenib, bevazizumab, everolimus and pazopanib. The control of the progress of the disease and the toxicity covered 44,3% of the patients. The toxicity of the 3–4th levels were registered during the treatment by inhibitors tyrozinkinaz. The target line therapy increased expenditures by 10% and allowed to increase overall survivability to 42 months.Conclusion: An electronic register of the patients provides monitoring, optimizes expenditures and increases the availability of the target therapy up to 19,7%. Sequential therapy is reasonable and provides the increase of the overall patients’ survivability. 

381: Promoter Hypermethylation Profile of Kidney Cancer with New Pro-Apoptotic P53 Target Genes and Possible Clinical Implications

2006 ◽  
Vol 175 (4S) ◽  
pp. 125-125
Author(s):  
Frank Christoph ◽  
Steffen Weikert ◽  
Carsten Kempkensteffen ◽  
Martin Schostak ◽  
Hans Krause ◽  
...  
Keyword(s):  
Kidney Cancer ◽  
Target Genes ◽  
Promoter Hypermethylation ◽  
Clinical Implications ◽  
P53 Target Genes

An Achilles heel for kidney cancer

Nature ◽  
2017 ◽  
Vol 547 (7664) ◽  
pp. 383-383
Keyword(s):  
Kidney Cancer

Stemming kidney cancer

Nature ◽  
2000 ◽  
Author(s):  
Helen Gavaghan
Keyword(s):  
Kidney Cancer
Sign in / Sign up

Export Citation Format

Share Document